April 10, 2026 - Apotex Corp. today announced it has received the first U.S. Food and Drug Administration (FDA) Tentative Approval for its Abbreviated New Drug Application (ANDA) for Semaglutide Injection, marking a significant milestone in expanding affordable access to complex peptide therapies for patients across the United States. This approval reinforces Apotex's leadership in bringing high value, technically challenging medicines that help improve patient access and support a more sustain

Advancing next-generation RNA therapeutics beyond the liver through breakthrough delivery technologies April 10, 2026 -- Vivatides Therapeutics, a global biotechnology company focused on developing extrahepatic RNA-targeting therapeutics, announced the successful closing of an oversubscribed $54 million Series A financing. The round was co-led by Qiming Venture Partners and a leading industry fund, with participation from Highlight Capital, a leading venture fund, and TF Capital. Existing inves

The company has enrolled 10 patients, marking early momentum in evaluating a novel, non-invasive, drug-centered therapeutic approach to brain cancer treatment. April 9, 2026 -- Alpheus Medical, Inc., a private, clinical-stage biotechnology company, today announced the initiation of its Phase 2b randomized controlled trial in newly diagnosed glioblastoma (nGBM) with 10 patients enrolled to date and additional clinical sites continuing to come online. Glioblastoma is a highly infiltrative brain

A New Hope for Patients with Advanced Gastric and Pancreatic Cancers April 9, 2026 -- A groundbreaking new CAR-T cell therapy for advanced gastrointestinal cancers is expected to become available in China in the first half of 2026, marking a major step forward in cancer treatment. Jiahui International Cancer Center will be among the leading medical institutions offering access to this innovative therapy for eligible patients. The therapy, known as satri-cel (CT041), is the world's first CAR-T

GSK discontinued Wellcovorin in 1999, but the FDA in September last year asked the pharma to re application, pointing to its potential to treat cerebral folate deficiency with “autistic features.” GSK has withdrawn an approval application for Wellcovorin, a decades-old drug that late last year gained renewed attention after the members of the Trump administration publicly suggested it has the potential to treat autism symptoms. The pharma requested to terminate the new drug application because

A San Diego biotech looking to double up on the power of antibody-drug conjugates with fewer toxicities has patched together a $137 million Series B from a group of blue-chip investors. The seven-employee startup, called Sidewinder Therapeutics, plans to make its mark by simultaneously engaging two targets and “overcoming fundamental limitations in the first-gen ADCs,” CEO Eric Murphy said in an interview. That includes avoiding off-target toxicities that arise when ADC payloads spill into the b

Partnering with Parent Project Muscular Dystrophy to ensure timely access to the trial for eligible patients ~15,000 children are living with DMD in the U.S. April 07, 2026 -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that the United States Food and Drug Administration (FDA) has granted Investigational New Drug (IND) clearance to directly proceed for a registrational clinical trial evaluating Ryoncil® (rem

First-in-class TET2 activator targets DNA damage response in GBM and other cancers Strong preclinical efficacy, brain penetration, and safety pro clinical advancement Study led by world-leading glioblastoma investigators, including Dr. Roger Stupp Hemispherian AS, a clinical-stage oncology company developing novel small molecule therapeutics, today announced the initiation of a first-in-human Phase 1/2a clinical trial of GLIX1 in patients with recurrent and progressive glioblastoma (GBM) and ot

April 7, 2026 -- Phanes Therapeutics, Inc. (Phanes), a clinical stage biotech company focused on innovative drug discovery and development in oncology, announced today the initiation of the dose expansion phase in their clinical study evaluating spevatamig in combination with chemotherapy for the treatment of biliary tract cancer (BTC), following dose-limiting toxicity (DLT) clearance at two dose levels. Spevatamig is a first-in-class native IgG-like bispecific antibody (bsAb) targeting claudin

April 7, 2026 -- ATLATL Innovation Center (hereinafter referred to as "ATLATL"), a global innovation platform for life science research and development, announced an agreement with Daiichi Sankyo to leverage ATLATL's multi-regional innovative R&D network and expertise in the Asia-Pacific biotech sector to help Daiichi Sankyo identify high-quality R&D platform technologies and accelerate the transformation and implementation of innovative science in order to potentially bring new treatment option